OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
History repeating: guidelines to address common problems in psychedelic science
Michiel van Elk, Eiko I. Fried
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 51
Michiel van Elk, Eiko I. Fried
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 51
Showing 1-25 of 51 citing articles:
Extended difficulties following the use of psychedelic drugs: A mixed methods study
Jules Evans, Oliver Robinson, Eirini K. Argyri, et al.
PLoS ONE (2023) Vol. 18, Iss. 10, pp. e0293349-e0293349
Open Access | Times Cited: 61
Jules Evans, Oliver Robinson, Eirini K. Argyri, et al.
PLoS ONE (2023) Vol. 18, Iss. 10, pp. e0293349-e0293349
Open Access | Times Cited: 61
Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin
Joshua D. Rosenblat, Shakila Meshkat, Zoe Doyle, et al.
Med (2024) Vol. 5, Iss. 3, pp. 190-200.e5
Closed Access | Times Cited: 28
Joshua D. Rosenblat, Shakila Meshkat, Zoe Doyle, et al.
Med (2024) Vol. 5, Iss. 3, pp. 190-200.e5
Closed Access | Times Cited: 28
Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications
Francesco Weiss, Anna Magnesa, Matteo Gambini, et al.
Brain Sciences (2025) Vol. 15, Iss. 2, pp. 117-117
Open Access | Times Cited: 4
Francesco Weiss, Anna Magnesa, Matteo Gambini, et al.
Brain Sciences (2025) Vol. 15, Iss. 2, pp. 117-117
Open Access | Times Cited: 4
A framework for assessment of adverse events occurring in psychedelic-assisted therapies
Roman Palitsky, Deanna M. Kaplan, John Perna, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 8, pp. 690-700
Closed Access | Times Cited: 11
Roman Palitsky, Deanna M. Kaplan, John Perna, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 8, pp. 690-700
Closed Access | Times Cited: 11
A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions
Bill Brennan, Alex R. Kelman, Alexander B. Belser
Psychedelic Medicine (2023) Vol. 1, Iss. 4, pp. 218-229
Open Access | Times Cited: 21
Bill Brennan, Alex R. Kelman, Alexander B. Belser
Psychedelic Medicine (2023) Vol. 1, Iss. 4, pp. 218-229
Open Access | Times Cited: 21
What Predicts Beneficial Outcomes in Psychedelic Use? A Quantitative Content Analysis of Psychedelic Health Outcomes
Elias C. Acevedo, Scott Uhler, Kaitlyn P. White, et al.
Journal of Psychoactive Drugs (2024), pp. 1-10
Closed Access | Times Cited: 6
Elias C. Acevedo, Scott Uhler, Kaitlyn P. White, et al.
Journal of Psychoactive Drugs (2024), pp. 1-10
Closed Access | Times Cited: 6
Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression
Daniel Meling, Rebecca Ehrenkranz, Sandeep M. Nayak, et al.
Psychoactives (2024) Vol. 3, Iss. 2, pp. 215-234
Open Access | Times Cited: 6
Daniel Meling, Rebecca Ehrenkranz, Sandeep M. Nayak, et al.
Psychoactives (2024) Vol. 3, Iss. 2, pp. 215-234
Open Access | Times Cited: 6
Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists
Julian D. Sandbrink, Kyle Johnson, Maureen Gill, et al.
AJOB Neuroscience (2024) Vol. 15, Iss. 2, pp. 82-89
Open Access | Times Cited: 5
Julian D. Sandbrink, Kyle Johnson, Maureen Gill, et al.
AJOB Neuroscience (2024) Vol. 15, Iss. 2, pp. 82-89
Open Access | Times Cited: 5
A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials
Ronit Kishon, Nadav Liam Modlin, Yael M. Cycowicz, et al.
npj Mental Health Research (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 4
Ronit Kishon, Nadav Liam Modlin, Yael M. Cycowicz, et al.
npj Mental Health Research (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 4
Unveiling Psychedelics: One of the Most Meaningful Events in Life Associated with Improved Well-Being in Swedish Users
Petri Kajonius, David Sjöström, Emma Claesdotter‐Knutsson
Journal of Psychoactive Drugs (2025), pp. 1-7
Open Access
Petri Kajonius, David Sjöström, Emma Claesdotter‐Knutsson
Journal of Psychoactive Drugs (2025), pp. 1-7
Open Access
Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials
Michelle Matvey, D. Parker Kelley, Ellen Bradley, et al.
JAMA Psychiatry (2025) Vol. 82, Iss. 3, pp. 311-311
Closed Access
Michelle Matvey, D. Parker Kelley, Ellen Bradley, et al.
JAMA Psychiatry (2025) Vol. 82, Iss. 3, pp. 311-311
Closed Access
An initiative for living evidence synthesis in clinical psychedelic research
S. Parker Singleton, Brooke L. Sevchik, Simon Vandekar, et al.
Nature Mental Health (2025) Vol. 3, Iss. 1, pp. 3-5
Closed Access
S. Parker Singleton, Brooke L. Sevchik, Simon Vandekar, et al.
Nature Mental Health (2025) Vol. 3, Iss. 1, pp. 3-5
Closed Access
A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research
David B. Yaden, Marianna Graziosi, Anna Owen, et al.
Psychedelic Medicine (2025)
Closed Access
David B. Yaden, Marianna Graziosi, Anna Owen, et al.
Psychedelic Medicine (2025)
Closed Access
Psychedelics: Safety and Efficacy
Norman Miller
International Journal of Environmental Research and Public Health (2025) Vol. 22, Iss. 2, pp. 134-134
Open Access
Norman Miller
International Journal of Environmental Research and Public Health (2025) Vol. 22, Iss. 2, pp. 134-134
Open Access
Safety and efficacy of methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in post-traumatic stress disorder: An overview of systematic reviews and meta-analyses
Alene Sze Jing Yong, Suzie Bratuskins, Musa Samir Sultani, et al.
Australian & New Zealand Journal of Psychiatry (2025)
Closed Access
Alene Sze Jing Yong, Suzie Bratuskins, Musa Samir Sultani, et al.
Australian & New Zealand Journal of Psychiatry (2025)
Closed Access
The intensity of the psychedelic experience is reliably associated with clinical improvements: a systematic review and meta-analysis
Bruno Roméo, E. Kervadec, Baptiste Fauvel, et al.
Neuroscience & Biobehavioral Reviews (2025) Vol. 172, pp. 106086-106086
Closed Access
Bruno Roméo, E. Kervadec, Baptiste Fauvel, et al.
Neuroscience & Biobehavioral Reviews (2025) Vol. 172, pp. 106086-106086
Closed Access
Current evidence for the role of rapid-acting antidepressants (RAAD) in bipolar depression? A perspective and plan for action
Jonathan Repple, Maximilian Bayas, Christine Möser, et al.
Biological Psychiatry (2025)
Open Access
Jonathan Repple, Maximilian Bayas, Christine Möser, et al.
Biological Psychiatry (2025)
Open Access
The Effects of Psychedelic-Assisted Therapy on Illness and Death Anxiety: A Systematic Review and Meta-Analysis
Aron Amaev, Jianmeng Song, Yasaman Kambari, et al.
Journal of Psychiatric Research (2025)
Closed Access
Aron Amaev, Jianmeng Song, Yasaman Kambari, et al.
Journal of Psychiatric Research (2025)
Closed Access
Classic Psychedelics for the Treatment of Depression: Potential Benefits and Challenges
Sharmin Ghaznavi, Steffen Richter
Drugs (2025)
Closed Access
Sharmin Ghaznavi, Steffen Richter
Drugs (2025)
Closed Access
Enhanced independence: De-biasing processes in psychedelic research and beyond
Katherine Cheung, Rebecca Ehrenkranz, David B. Yaden
Research Ethics (2025)
Open Access
Katherine Cheung, Rebecca Ehrenkranz, David B. Yaden
Research Ethics (2025)
Open Access
Leveraging meditation research for the study of psychedelic-related adverse effects
Roman Palitsky, Nicholas K. Canby, Nicholas T. Van Dam, et al.
International Review of Psychiatry (2024), pp. 1-15
Closed Access | Times Cited: 3
Roman Palitsky, Nicholas K. Canby, Nicholas T. Van Dam, et al.
International Review of Psychiatry (2024), pp. 1-15
Closed Access | Times Cited: 3
Psychedelics in PERIL: The Commercial Determinants of Health, Financial Entanglements and Population Health Ethics
Daniel Z. Buchman, Daniel Rosenbaum
Public Health Ethics (2024) Vol. 17, Iss. 1-2, pp. 24-39
Open Access | Times Cited: 2
Daniel Z. Buchman, Daniel Rosenbaum
Public Health Ethics (2024) Vol. 17, Iss. 1-2, pp. 24-39
Open Access | Times Cited: 2
A Framework for Assessment of Adverse Events Occurring in Psychedelic Assisted Therapies
Roman Palitsky, Deanna M. Kaplan, John Perna, et al.
(2024)
Open Access | Times Cited: 2
Roman Palitsky, Deanna M. Kaplan, John Perna, et al.
(2024)
Open Access | Times Cited: 2
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat
Daniel Meling, Klemens Egger, Helena D. Aicher, et al.
Journal of Psychopharmacology (2024)
Closed Access | Times Cited: 2
Daniel Meling, Klemens Egger, Helena D. Aicher, et al.
Journal of Psychopharmacology (2024)
Closed Access | Times Cited: 2
Psychedelics and the treatment of eating disorders: considerations for future research and practice
Émilie Lacroix, Karsten Fatur, Phillipa Hay, et al.
Journal of Eating Disorders (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 2
Émilie Lacroix, Karsten Fatur, Phillipa Hay, et al.
Journal of Eating Disorders (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 2
